'Dirty' cancer biotech startup cleans up in $525M build-to-buy deal with big pharma

Maverick's drugs — two of which enter clinical trials this year — are aimed at precisely attacking tumors in head and neck, lung, breast, prostate and other cancers while leaving nearby healthy tissue untouched.
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news